***Background.*** Combination vaccines simplify vaccination visits and improve coverage and timeliness. DTaP5-IPV-Hib-HepB is an investigational, fully-liquid, combination vaccine designed to protect against 6 diseases.

***Methods.*** In this multicenter, open-label, comparator-controlled, Phase III study, healthy infants were randomized 2:1 to receive one of the following immunization regimens:

  Group                     Age                        
  ------------------------- -------------------------- ------------------
  1                         DTaP5-IPV-Hib-HepB         Daptacel (DTaP5)
  Prevnar 13 (PCV13)        PedvaxHIB (PRP-OMPC)       
  RotaTeq (RV5)             Prevnar 13 (PCV13)         
  2                         Pentacel (DTaP5-IPV/Hib)   
  Recombivax HB (HepB)^†^   Daptacel (DTaP5)           
  Prevnar 13 (PCV13)        ActHIB (PRP-T)             
  RotaTeq (RV5)             Prevnar 13 (PCV13)         

^†^Dose not given at 4 mo.

***Results.*** All infants received HepB in the first month of life. A total of 981 subjects were vaccinated in Group 1 and 484 in Group 2. In a per-protocol analysis, immune responses to all DTaP5-IPV-Hib-HepB antigens 1 month after dose 3 were non-inferior in Group 1 as compared to Group 2, with the exception of anti-filamentous hemagglutinin (FHA, a pertussis antigen) GMTs (46.59 vs 72.28, ratio 0.64 \[95% CI 0.59, 0.70\]). Vaccine response rates for FHA were non-inferior to control. After the toddler dose, Group 1 was non-inferior to Group 2 for all pertussis antigens. Group 1 response to concomitant RV5, measured as anti-rotavirus IgA GMT 1 month after dose 3, was also non-inferior.

Solicited adverse event rates after any dose were similar in both groups, with the exceptions of increased injection-site erythema (48.8% vs 42.2%, difference 6.5% \[1.1, 11.9\]), increased fever (47.4% vs 34.4%, difference 13.1% \[7.7, 18.3\]), and decreased appetite (48.9% vs 43.3%, difference 5.6% \[0.2, 11.0\]) in Group 1. Most adverse events were mild-to-moderate and did not lead to subject withdrawal. Fever was not associated with hospitalization or seizures.

***Conclusion.*** The safety and immunogenicity of DTaP5-IPV-Hib-HepB is comparable to the analogous licensed component vaccines. Decreased anti-FHA GMTs and increased injection-site reactions and fever are unlikely to be clinically significant. DTaP5-IPV-Hib-HepB provides a new hexavalent option for pediatric combination vaccines, aligned with recommended US immunizations.
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